Cargando…
Hypercalcaemia after treatment with denosumab in children: bisphosphonates as an option for therapy and prevention?
BACKGROUND: Pharmacologic options for treatment of osteolytic diseases especially in children are limited. Although not licensed for use, denosumab, a fully humanized antibody to RANKL, is used in children with good effects. Among others, one possible indication are giant cell tumors and aneurysmati...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Singapore
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515853/ https://www.ncbi.nlm.nih.gov/pubmed/32776272 http://dx.doi.org/10.1007/s12519-020-00378-w |